141 related articles for article (PubMed ID: 2386109)
1. Differences in the effects of the antirheumatic drugs, bucillamine and D-penicillamine, on mitogen-induced proliferation of mouse spleen cells.
Mita S; Matsunaga K
Agents Actions; 1990 Jun; 30(3-4):363-8. PubMed ID: 2386109
[TBL] [Abstract][Full Text] [Related]
2. Effects of KE-758; an active metabolite of the new anti-rheumatic drug KE-298, D-penicillamine, bucillamine and auranofin on the proliferation of murine lymphocytes, and the production of nitric oxide by murine macrophages.
Inoue T; Takeshita K; Fukushima K
Int Immunopharmacol; 2001 May; 1(5):833-42. PubMed ID: 11379039
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mitogen-induced response of human peripheral blood mononuclear cells by bucillamine, a new antirheumatic sulfhydryl drug.
Akamatsu T; Matsubara T; Saegusa Y; Mizuno K
Rheumatol Int; 1994; 13(5):197-201. PubMed ID: 8202663
[TBL] [Abstract][Full Text] [Related]
4. Regulation of B cell function by bucillamine, a novel disease-modifying antirheumatic drug.
Hirohata S; Lipsky PE
Clin Immunol Immunopathol; 1993 Jan; 66(1):43-51. PubMed ID: 8440072
[TBL] [Abstract][Full Text] [Related]
5. Bucillamine suppresses human Th1 cell development by a hydrogen peroxide-independent mechanism.
Morinobu A; Wang Z; Kumagai S
J Rheumatol; 2000 Apr; 27(4):851-8. PubMed ID: 10782806
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolites.
Hashimoto K; Lipsky PE
J Rheumatol; 1993 Jun; 20(6):953-7. PubMed ID: 8350330
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo inhibition of activation induced T cell apoptosis by bucillamine.
Okazaki H; Sato H; Kamimura T; Hirata D; Iwamoto M; Yoshio T; Mimori A; Masuyama JI; Kano S; Minota S
J Rheumatol; 2000 Jun; 27(6):1358-64. PubMed ID: 10852254
[TBL] [Abstract][Full Text] [Related]
8. Effect of bucillamine (SA96) on type II collagen induced arthritis in rats.
Hayashi M; Matsunaga K; Okahara A; Mita S
J Rheumatol; 1991 May; 18(5):691-5. PubMed ID: 1865415
[TBL] [Abstract][Full Text] [Related]
9. Formation of DNA strand breaks by D-penicillamine and bucillamine in human lymphocytes.
Yamanaka H; Hakoda M; Kamatani N; Kashiwazaki S; Carson DA
Immunopharmacology; 1993; 26(2):113-8. PubMed ID: 8282535
[TBL] [Abstract][Full Text] [Related]
10. Bucillamine inhibits T cell adhesion to human endothelial cells.
Eguchi K; Kawakami A; Ida H; Nakashima M; Yamashita I; Sakai M; Shimada H; Terada K; Fukuda T; Ishimaru T
J Rheumatol; 1992 Jul; 19(7):1045-50. PubMed ID: 1512757
[TBL] [Abstract][Full Text] [Related]
11. Modulatory effect of bucillamine (SA96) on interleukin-1-and/or -2-induced proliferation of T lymphocytes.
Sasano M; Goto M; Nishioka K
Agents Actions; 1990 Nov; 31(3-4):285-9. PubMed ID: 2085145
[TBL] [Abstract][Full Text] [Related]
12. Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine.
Aono H; Hasunuma T; Fujisawa K; Nakajima T; Yamamoto K; Mita S; Nishioka K
J Rheumatol; 1996 Jan; 23(1):65-70. PubMed ID: 8838510
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine.
Matsubara T; Saura R; Hirohata K; Ziff M
J Clin Invest; 1989 Jan; 83(1):158-67. PubMed ID: 2463265
[TBL] [Abstract][Full Text] [Related]
14. Free-radical degradation of high-molecular-weight hyaluronan induced by ascorbate plus cupric ions. Testing of bucillamine and its SA981-metabolite as antioxidants.
Valachová K; Hrabárová E; Priesolová E; Nagy M; Baňasová M; Juránek I; Soltés L
J Pharm Biomed Anal; 2011 Nov; 56(3):664-70. PubMed ID: 21782370
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological effects of SA96 (bucillamine) and its metabolites as immunomodulating drugs--the disulfide structure of SA-96 metabolites plays a critical role in the pharmacological action of the drug.
Matsuno H; Sugiyama E; Muraguchi A; Nezuka T; Kubo T; Matsuura K; Tsuji H
Int J Immunopharmacol; 1998 Jun; 20(6):295-304. PubMed ID: 9754677
[TBL] [Abstract][Full Text] [Related]
16. Novel in vitro effects of bucillamine: inhibitory effects on proinflammatory cytokine production and transendothelial migration of T cells.
Munakata Y; Iwata S; Dobers J; Ishii T; Nori M; Tanaka H; Morimoto C
Arthritis Rheum; 2000 Jul; 43(7):1616-23. PubMed ID: 10902767
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory mechanism of vascular endothelial growth factor (VEGF) by bucillamine.
Koyama S; Takagi H; Otani A; Oh H; Nishimura K; Honda Y
Br J Pharmacol; 2002 Nov; 137(6):901-9. PubMed ID: 12411422
[TBL] [Abstract][Full Text] [Related]
18. Effects of bucillamine, a new anti-rheumatic drug, on the experimental autoimmune uveitis in rats.
Sawa K; Mochizuki M
Exp Eye Res; 1994 Apr; 58(4):431-8. PubMed ID: 7925680
[TBL] [Abstract][Full Text] [Related]
19. D-penicillamine: mitogenic effect on mouse, rat and human spleen lymphocytes.
Claësson MH; Hansen GS; Tjell V
Med Microbiol Immunol; 1979 Aug; 167(3):161-74. PubMed ID: 315028
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphocyte proliferation by copper- or ceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes.
Lipsky PE
J Clin Invest; 1984 Jan; 73(1):53-65. PubMed ID: 6606652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
